These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25186610)

  • 21. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.
    Kao KR; Popadiuk P; Thoms J; Aoki S; Anwar S; Fitzgerald E; Andrews P; Voisey K; Gai L; Challa S; He Z; Gonzales-Aguirre P; Simmonds A; Popadiuk C
    J Clin Pathol; 2018 May; 71(5):402-411. PubMed ID: 28924059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients.
    Taeb J; Asgari M; Abolhasani M; Farajollahi MM; Madjd Z
    Pathol Res Pract; 2014 Jan; 210(1):18-23. PubMed ID: 24183365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between clinical significance of serum proinflammatory protein interleukin-6 and classic tumor markers total PSA, free PSA and free/total PSA prior to prostate biopsy.
    Milicević N; Mrcela M; Lukić I; Mandić S; Horvat V; Galić J
    Coll Antropol; 2014 Mar; 38(1):147-50. PubMed ID: 24851609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics.
    Kim EA; Kim YH; Kang HW; Yoon HY; Kim WT; Kim YJ; Yun SJ; Moon SK; Choi YH; Kim IY; Lee SC; Kim WJ
    J Korean Med Sci; 2015 Jul; 30(7):937-42. PubMed ID: 26130958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
    Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
    J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy.
    Nejadmoghaddam MR; Zarnani AH; Ghahremanzadeh R; Ghods R; Mahmoudian J; Yousefi M; Nazari M; Ghahremani MH; Abolhasani M; Anissian A; Mahmoudi M; Dinarvand R
    Sci Rep; 2017 Oct; 7(1):13373. PubMed ID: 29042604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
    Herawi M; De Marzo AM; Kristiansen G; Epstein JI
    Hum Pathol; 2007 Jan; 38(1):72-8. PubMed ID: 16949907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
    Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
    Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions.
    Levakov AF; Kaćanski MM; Vucković N; Zivojinov M; Amidzić J; Sabo JI
    Vojnosanit Pregl; 2015 Oct; 72(10):906-13. PubMed ID: 26665557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
    Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
    Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.
    Marchal C; Redondo M; Padilla M; Caballero J; Rodrigo I; García J; Quian J; Boswick DG
    Histol Histopathol; 2004 Jul; 19(3):715-8. PubMed ID: 15168332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance].
    Liu BQ; Wu YD; Wei JX; Zhang T; Liu RL; Ma TX
    Zhonghua Nan Ke Xue; 2007 Nov; 13(11):997-1001. PubMed ID: 18077911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.
    Kalantari E; Asgari M; Nikpanah S; Salarieh N; Asadi Lari MH; Madjd Z
    Pathol Oncol Res; 2017 Oct; 23(4):793-802. PubMed ID: 28083789
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Kim YH; Byun YJ; Kim WT; Jeong P; Yan C; Kang HW; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
    J Korean Med Sci; 2018 Nov; 33(47):e303. PubMed ID: 30450027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
    Saito S; Egawa S; Endoh M; Ueno S; Ito A; Numahata K; Satoh M; Kuwao S; Baba S; Hakomori S; Arai Y
    Int J Cancer; 2005 May; 115(1):105-13. PubMed ID: 15704108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
    Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.